Ordinary Rebalance | Solactive China Healthcare Disruption Index | Effective Date 1st September 2023
In the ordinary rebalance, the following composition will be implemented effective open 01.09.2023:
| 3D MEDICINES INC |
| 3SBIO INC |
| AKESO INC |
| ALIBABA HEALTH INFORMATION TECHNOLOGY LTD |
| ANGELALIGN TECHNOLOGY INC |
| CANSINO BIOLOGICS INC |
| CHINA MEDICAL SYSTEM HOLDINGS LTD |
| CSPC PHARMACEUTICAL GROUP LTD |
| GENSCRIPT BIOTECH CORP |
| GIANT BIOGENE HOLDING CO LTD |
| GRAND PHARMACEUTICAL GROUP LTD |
| GUSHENGTANG HOLDINGS LTD |
| HANSOH PHARMACEUTICAL GROUP CO |
| INNOCARE PHARMA LTD |
| INNOVENT BIOLOGICS INC |
| JD HEALTH INTERNATIONAL INC |
| JOINN LABORATORIES CHINA C-H |
| KEYMED BIOSCIENCES INC |
| LIFETECH SCIENTIFIC CORP |
| LIVZON PHARMACEUTICAL GROUP INC |
| LUYE PHARMA GROUP LTD |
| MICROPORT SCIENTIFIC CORP |
| PING AN HEALTHCARE AND TECHNOL |
| REMEGEN CO LTD-H |
| SHANDONG WEIGAO GROUP MEDICAL POLYMER CO LTD |
| SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD |
| SHANGHAI JUNSHI BIOSCIENCES CO LTD |
| SHANGHAI MICROPORT MEDBOT GR |
| SIMCERE PHARMACEUTICAL GROUP |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SKB BIO-B ORD H |
| WUXI APPTEC CO LTD |
| WUXI BIOLOGICS CAYMAN INC |
| YSB ORD |
| ZAI LAB LTD |